• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Three-dimensional molecular shape analysis-quantitative structure-activity relationship of a series of cholecystokinin-A receptor antagonists.

作者信息

Tokarski J S, Hopfinger A J

机构信息

Department of Medicinal Chemistry and Pharmacognosy (M/C 781), College of Pharmacy, University of Illinois at Chicago 60612-7231.

出版信息

J Med Chem. 1994 Oct 14;37(21):3639-54. doi: 10.1021/jm00047a021.

DOI:10.1021/jm00047a021
PMID:7932591
Abstract

The three-dimensional molecular shape analysis-quantitative structure-activity relationship (3D-MSA-QSAR) technique has been applied to develop correlations between the calculated physicochemical properties and the in vitro activities of a series of 3-(acylamino)-5-phenyl-2H-1,4-benzodiazepine cholecystokinin-A (CCK-A) antagonists. 3D-MSA-QSARs were developed for varying subsets of 53 analogs (J. Med. Chem. 1988, 31, 2235-2246). An active conformation is hypothesized for these compounds using the loss in biological activity-loss in conformational stability principle. After placing all compounds in the active conformation and performing pairwise molecular shape analysis, it was determined that not any one analog serves as the best shape reference compound. Nonidentical volumes of allowed receptor space are mapped out by different antagonists. A shape reference compound that consists of selected overlapped structures expands the definition of the accessible receptor space. This type of mutant improves the predicted activity of analogs over the value predicted if only one compound is chosen as the reference. Molecular shape, as represented by common overlap steric volume and nonoverlap steric volume, is the major factor contributing to the affinity of this class of compounds. Intramolecular conformational stability, as measured by the difference in energy of the active conformation and the global minimum energy conformation, is also important. It is further concluded from the 3D-MSA-QSAR models that part of the binding pocket for the 3-amido substituent has a preference for lipophilicity. The method used in this study of fragmenting the antagonist into spheres of varying radii and measuring lipophilicity isolates the substructure with highest probability of interacting with the receptor. Two indicator variables marking the presence of an N-methyl group and an o-fluoro atom on the 5'-phenyl substituent of the benzodiazepine ring structure also contribute significantly to the 3D-MSA-QSAR models. The 3D-MSA-QSAR results have led to the proposal of a 3D pharmacophore model for the benzodiazepine CCK-A antagonists.

摘要

相似文献

1
Three-dimensional molecular shape analysis-quantitative structure-activity relationship of a series of cholecystokinin-A receptor antagonists.
J Med Chem. 1994 Oct 14;37(21):3639-54. doi: 10.1021/jm00047a021.
2
Quantitative structure-activity relationship study on some nonpeptidal cholecystokinin antagonists.一些非肽类胆囊收缩素拮抗剂的定量构效关系研究
Bioorg Med Chem. 1999 Jun;7(6):1127-30. doi: 10.1016/s0968-0896(99)00013-9.
3
Exploring 3D-QSAR of thiazole and thiadiazole derivatives as potent and selective human adenosine A3 receptor antagonists+.探索噻唑和噻二唑衍生物作为强效和选择性人腺苷A3受体拮抗剂的3D-QSAR+。
J Mol Model. 2005 Nov;11(6):516-24. doi: 10.1007/s00894-005-0273-6. Epub 2005 Jun 1.
4
A molecular shape analysis and quantitative structure-activity relationship investigation of some triazine-antifolate inhibitors of Leishmania dihydrofolate reductase.
Arch Biochem Biophys. 1988 Oct;266(1):152-61. doi: 10.1016/0003-9861(88)90245-7.
5
Synthesis and SAR of new 5-phenyl-3-ureido-1,5-benzodiazepines as cholecystokinin-B receptor antagonists.新型5-苯基-3-脲基-1,5-苯并二氮杂䓬类作为胆囊收缩素-B受体拮抗剂的合成与构效关系
J Med Chem. 2000 Oct 5;43(20):3596-613. doi: 10.1021/jm990967h.
6
Potent and subtype-selective CCK-B/gastrin receptor antagonists: 2,4-dioxo-1,5-benzodiazepines with a plane of symmetry.
Bioorg Med Chem. 1997 Jul;5(7):1433-46. doi: 10.1016/s0968-0896(97)00083-7.
7
Construction of a molecular shape analysis-three-dimensional quantitative structure-analysis relationship for an analog series of pyridobenzodiazepinone inhibitors of muscarinic 2 and 3 receptors.构建毒蕈碱2和3受体的吡啶并苯二氮杂䓬酮抑制剂类似物系列的分子形状分析-三维定量构效关系。
J Med Chem. 1994 Oct 28;37(22):3775-88. doi: 10.1021/jm00048a014.
8
A 3D-QSAR study of anticoccidial triazines using molecular shape analysis.利用分子形状分析对抗球虫三嗪类化合物进行的三维定量构效关系研究。
J Chem Inf Comput Sci. 1995 Jul-Aug;35(4):771-8. doi: 10.1021/ci00026a016.
9
Quantitative structure-activity relationship studies on 5-phenyl-3-ureido-1,5-benzodiazepine as cholecystokinin-A receptor antagonists.5-苯基-3-脲基-1,5-苯二氮䓬作为胆囊收缩素-A受体拮抗剂的定量构效关系研究
Bioorg Med Chem. 2002 Nov;10(11):3571-81. doi: 10.1016/s0968-0896(02)00167-0.
10
Quantitative structure-activity relationship studies on cholecystokinin antagonists.
Curr Pharm Des. 2002;8(2):111-24. doi: 10.2174/1381612023396500.

引用本文的文献

1
A comprehensive analysis of the thermodynamic events involved in ligand-receptor binding using CoRIA and its variants.使用CoRIA及其变体对配体-受体结合所涉及的热力学事件进行全面分析。
J Comput Aided Mol Des. 2008 Feb;22(2):91-104. doi: 10.1007/s10822-008-9172-0. Epub 2008 Jan 25.
2
A hydrophobic similarity analysis of solvation effects on nucleic acid bases.核酸碱基溶剂化效应的疏水相似性分析。
J Mol Model. 2007 Feb;13(2):357-65. doi: 10.1007/s00894-006-0150-y. Epub 2006 Sep 21.
3
Comparative residue interaction analysis (CoRIA): a 3D-QSAR approach to explore the binding contributions of active site residues with ligands.
比较残基相互作用分析(CoRIA):一种用于探索活性位点残基与配体结合贡献的3D-QSAR方法。
J Comput Aided Mol Des. 2006 Jun;20(6):343-60. doi: 10.1007/s10822-006-9051-5. Epub 2006 Sep 29.
4
CoMFA and CoMSIA 3D-quantitative structure-activity relationship model on benzodiazepine derivatives, inhibitors of phosphodiesterase IV.
J Comput Aided Mol Des. 2001 Sep;15(9):767-85. doi: 10.1023/a:1013104713913.